PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma

Watcharin Loilome1, Sirinun Juntana, Nisana Namwat

  • 1Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Insights

Targeting the PRKAR1A/PKAI pathway inhibits cholangiocarcinoma (CCA) cell growth. Silencing PRKAR1A/PKAI induced apoptosis and reduced oncogenic signaling, suggesting PRKAR1A/PKAI as a potential CCA therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The PRKAR1A/PKAI pathway is implicated in various cancers.
  • Its specific role in cholangiocarcinoma (CCA) growth remains largely undefined.

Purpose of the Study:

  • To investigate the effect of targeting PRKAR1A/PKAI on CCA cell proliferation.
  • To elucidate the molecular mechanisms underlying PRKAR1A/PKAI's role in CCA.

Main Methods:

  • Real-time PCR and immunohistochemistry to assess PRKAR1A and PRKAR2B expression in CCA tissues and cell lines.
  • Gene silencing of PRKAR1A and inhibition of PKA signaling.
  • Analysis of downstream signaling pathways including MAPK, PI3K/Akt, JAK/STAT, and Wnt/β-catenin.

Main Results:

  • PRKAR1A/PKAI was upregulated, while PRKAR2B/PKAII was downregulated in CCA.
  • PRKAR1A silencing significantly inhibited CCA cell proliferation and induced apoptosis.
  • Targeting PRKAR1A/PKAI reduced activity in key oncogenic signaling pathways.

Conclusions:

  • PRKAR1A/PKA overexpression drives human CCA cell growth through specific molecular pathways.
  • Abrogating PRKAR1A/PKA expression effectively inhibits CCA cell growth, induces apoptosis, and suppresses oncogenic signaling.
  • PRKAR1A presents a promising therapeutic target for CCA treatment.